INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Leveraging Technology in Phase I Clinical Trials

Ana Palijan, PhD

Ana Palijan, PhD

Director, Early Phase and Translational Research

Author picture

In the ever-evolving landscape of clinical research, Phase I studies are becoming increasingly complex. We’re proud to announce that two of our trailblazing colleagues, Ana Palijan, Director, Early Phase and Translational Research, and Éric Hardy, Senior Director, Biometrics, have contributed to a groundbreaking white paper that explores these complexities. Their expert analysis highlights the challenges and opportunities within Phase I trials, offering valuable insights for industry professionals.

Key Highlights:

  • In-depth Analysis: Explore the intricacies of Phase I studies, providing a comprehensive overview of the current landscape.
  • Expert Opinions: Gain insights from leading professionals who are at the forefront of clinical research.
  • Future Trends: Understand the emerging trends and how they might impact the future of Phase I trials.

This white paper is a must-read for anyone involved in clinical research. Whether you’re a seasoned professional or new to the field, the insights provided will enhance your understanding and approach to Phase I studies.

Dive into this white paper now!

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.